Credit Suisse’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Credit Suisse’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-9,067	Closed	-$392K	–	4509
2015 Q3	$392K	Sell	9,067 -28,578	-76%	-$1.21M	﹤0.01%	3571
2015 Q2	$1.59M	Buy	37,645 +10,064	+36%	+$424K	﹤0.01%	2750
2015 Q1	$1.07M	Sell	27,581 -145,517	-84%	-$5.6M	﹤0.01%	2911
2014 Q4	$5.83M	Sell	173,098 -133,999	-44%	-$4.73M	0.01%	1643
2014 Q3	$10.8M	Buy	307,097 +63,419	+26%	+$2.17M	0.01%	1251
2014 Q2	$8.01M	Sell	243,678 -91,942	-27%	-$3.15M	0.01%	1568
2014 Q1	$12.4M	Buy	335,620 +39,269	+13%	+$1.44M	0.01%	1118
2013 Q4	$11.4M	Sell	296,351 -65,782	-18%	-$2.08M	0.01%	1173
2013 Q3	$9.92M	Buy	362,133 +27,122	+8%	+$643K	0.01%	1140
2013 Q2	$7.04M	Buy	+335,011	New	+$6.54M	0.01%	1345

Other funds holding WX

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Credit Suisse's WX Position: Q4 2015 in Review

Credit Suisse sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 9,067 shares — an estimated $392K sold.

Credit Suisse first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $12.4M in Q1 2014. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

Credit Suisse reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
Credit Suisse sold 9,067 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $392K.
Credit Suisse first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
Credit Suisse's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $12.4M in Q1 2014.
2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Credit Suisse's 13F filing for Q4 2015, filed 16 Feb 2016.